Search results for "Highlights"

Results 51 - 60 of about 418 for "Highlights".
Sort by: Relevance | Newest | Oldest

SGLT-2 inhibitors associated with reduced heart failure events versus metformin

A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
10 Jun 2022

Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says

Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
10 Jun 2022

Cystatin C levels associated with risk of sight-threatening diabetic retinopathy

The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
13 May 2022

HbA1c, CGM data significantly differed in patients with kidney disease

Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
13 May 2022

Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists

One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
13 May 2022

Manufacturer's trials find positive results for combo drug for type 2 diabetes

Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
9 Jul 2021

Statins compared for non-HDL cholesterol levels in patients with diabetes

Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
8 Apr 2022

Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes

An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
8 Apr 2022

Recent articles address federal diabetes programs, type 1 diabetes care

The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
11 Mar 2022

GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases

A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
8 Apr 2022

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next